Sugi Predict

Sugi Predict / Compounds / SCHEMBL17593755

SCHEMBL17593755

SCHEMBL17593755

c1cncc(-c2ccnc3[nH]c(-c4n[nH]c5ccc(-c6cncc(OCCN7CCCC7)c6)cc45)nc23)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 8/20 0.68
▸ CLK2 P49760 7/20 0.68
▸ CLK3 P49761 5/20 0.68
▸ WNT1 P04628 13/20 0.68
▸ GAK O14976 1/20 0.53
▸ DYRK3 O43781 1/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ PRKD3 O94806 1/20 0.53
▸ MAP4K4 O95819 1/20 0.53
▸ NQO2 P16083 1/20 0.53
▸ CSNK2A2 P19784 1/20 0.53
▸ FECH P22830 1/20 0.53
▸ JAK1 P23458 1/20 0.53
▸ TYK2 P29597 1/20 0.53
▸ MAPK8 P45983 1/20 0.53
▸ MAPK9 P45984 1/20 0.53
▸ CSNK1A1 P48729 1/20 0.53
▸ CSNK1D P48730 1/20 0.53
▸ CSNK1E P49674 1/20 0.53
▸ CLK1 P49759 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17594056 0.93 DYRK1A (0.66) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17593685 0.93 WNT1 (0.80) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17593762 0.92 WNT1 (0.69) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17564647 0.92 WNT1 (0.59) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17639736 0.91 WNT1 (0.61) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17594210 0.91 WNT1 (0.68) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17639739 0.90 WNT1 (0.62) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17594060 0.90 CLK2 (0.65) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL17594037 0.90 WNT1 (0.64) DYRK1ACLK2CLK3WNT1GAK
SCHEMBL18380486 0.90 WNT1 (0.72) DYRK1ACLK2CLK3WNT1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-07 — — US claimed
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US claimed
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-07-17 — — US claimed
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-05-31 — — US claimed
US-9738638-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-08-22 — — US claimed
WO-2016040185-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO claimed
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-05-07 — — US disclosed
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2019-02-21 — — US disclosed
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-07-17 — — US disclosed
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-07-17 — — US disclosed
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-05-31 — — US disclosed
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-05-31 — — US disclosed
US-9738638-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-08-22 — — US disclosed
US-9738638-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-08-22 — — US disclosed
US-20160090380-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-31 — — US disclosed
US-20160090380-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148444-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 707/4885CLK2 907/4885CLK3 745/4885
US-10280166-B2 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A DYRK1A 707/4885CLK2 907/4885CLK3 745/4885
US-20190055238-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 707/4885CLK2 907/4885CLK3 745/4885
US-20160090380-A1 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 707/4885CLK2 907/4885CLK3 745/4885
US-10023572-B2 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A DYRK1A 707/4885CLK2 907/4885CLK3 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.